References
- https://covid19.who.int/
- Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet
Respir Med. 2020;8(4):e24.
- Henry BM, Lippi G. Poor survival with extracorporeal membrane
oxygenation in acute respiratory distress syndrome (ARDS) due to
coronavirus disease 2019 (COVID-19): Pooled analysis of early reports.
J Crit Care. 2020;58:27-28.
- Schmidt M, Tachon G, Devilliers C, et al. Blood oxygenation and
decarboxylation determinants during venovenous ECMO for respiratory
failure in adults. Intensive Care Med. 2013;39(5):838-46.
- Bonow RO, Fonarow GC, O’gara PT, Yancy CW. Association of Coronavirus
Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA
Cardiol. 2020
- Klok FA, Kruip MJHA, Van der meer NJM, et al. Incidence of thrombotic
complications in critically ill ICU patients with COVID-19. Thromb
Res. 2020
- Li X, Guo Z, Li B, et al. Extracorporeal Membrane Oxygenation for
Coronavirus Disease 2019 in Shanghai, China. ASAIO J. 2020
Figure1 : Patient selection, evaluation, and treatment strategies.
ARDS= acute respiratory distress syndrome, CKD=chronic kidney disease,
CHF=congestive heart failure, PEEP=positive end expiratory pressure,
ECMO=extracorporeal membrane oxygenation, PAO2=partial pressure of
oxygen , PCO2=partial pressure of carbon dioxide, DO2 = oxygen delivery.
VO2 = oxygen consumption. V/Q = ventilation/perfusion.